Six-Month Toxicity Study of Oral Administration of D-003 in Sprague Dawley Rats
Tóm tắt
Background: D-003 is a mixture of high molecular weight aliphatic primary acids purified from sugarcane wax (Saccharum officinarum) having cholesterol-lowering and antiplatelet effects.
Aim: This study was undertaken to investigate the toxicity induced by long-term oral administration of D-003 for 6 months to Sprague Dawley rats of both sexes.
Methods: Rats were randomly divided into four groups (20 rats of each sex/group): a control group, which received the vehicle, and three treatment groups, which received oral D-003 at doses of 250, 500 and 1000 mg/kg/day, respectively. Daily clinical observations and control of bodyweight and food consumption were conducted throughout the study period. On completion of active treatment, animals were sacrificed. Pharmacological effects associated with D-003 such as inhibition of platelet aggregation and increase in bleeding time were assessed in two satellite groups (14 animals of each sex/group): a control group and a group treated with the highest dose of D-003. Assessments of platelet aggregation to collagen were performed at baseline and at 6 months, and assessments of bleeding time were done at baseline, after 3 and 6 months of treatment, and after 30 days’ washout.
Results: As expected, D-003 significantly inhibited platelet aggregation. Bleeding time was increased after 3 months of treatment with D-003; this increase was maintained at 6 months, and was reversible after washout. Coagulation factors such as prothrombin time and kaolin-activated thromboplastin-time, which were determined in eight male animals from each group, were unaffected by D-003. Data analyses of bodyweight gain, food consumption, clinical observations, blood biochemistry, haematology, organ weight ratios and histopathological findings did not show trends related to D-003 dose or significant differences between control and treated groups.
Conclusion: It was concluded that the highest studied dose of D-003 (1000 mg/kg /day) represented a non-toxic dose level in the present chronic toxicity study in rats.
Tài liệu tham khảo
Murray CJL, López AD. Alternate projections of mortality and disability by cause 1990–2020: global burden disease study. Lancet 1997; 349: 1498–504
Anderson KM, Wilson PWF, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. Circulation 1991; 83: 356–62
Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: I. Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351–64
Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: II. The relationship of reduction in the incidence of coronary heart disease to cholesterol-lowering. JAMA 1984; 251: 365–74
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1 383–9
Sacks FM, Pfeffer MA, Moy LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9
Tonkin A, Aylward P, Colqhoun D, et al. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57
Shepherd S, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7
Downs JR, Clearfield M, Weiss S, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106
Schafer A. Antiplatelet therapy. Am J Med 1996; 101: 199–209
Witztum JL, Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785–92
Endemann G, Stanton LW, Madden KS, et al. CD 36 is a receptor for oxidized low-density lipoprotein. J Biol Chem 1993; 268: 11811–4
Brown MS, Goldstein JL. Scavenging for receptors. Nature (London) 1990; 342: 508–9
González L, Marrero D, Laguna A, et al., inventors. Laboratorios Dalmer SA, assignee. Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses. Republic of South Africa patent 98-2744. 1998 Dec 30
Gámez R, Mendoza S, Más R, et al. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr Ther Res Clin Exp 2000; 61: 8–16
Mendoza S, Gámez R, Noa M, et al. The effects of D-003 and policosanol on the lipid profile and endothelemia cells in normocholesterolemic rabbits: a head to head comparison. Curr Ther Res 2001; 62: 209–220
Menéndez R, Más R, Amor AM, et al. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol Res 2001; 44: 299–304
Menéndez R, Mas R, Pérez Y, et al. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003, a mixture of very long chain saturated fatty a. Can J Physiol Pharmacol. In press
Molina V, Arruzazabala ML, Carbajal D, et al. Antithrombotic effects of D003. Pharmacol Res 2000; 42: 137–43
Molina V, Arruzazabala ML, Carbajal D, Mas R. D-003, a new compound with effects on arachidonic acid metabolites. Prostaglandins Leukot Essent Fatty Acids 2002. In press
Castaño G, Mas R, Fernández L, et al. Assessment of the effects of D-003, a new antiplatelet and lipid-lowering compound, in healthy volunteers. Drugs R&D 2002; 3: 337–348
Gerson R, MacDonald J, Alberts W, et al. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl coenzyme A reductase inhibitors. Am J Med 1989; 87 Suppl 4a: 28–38
MacDonald J, Gerson R, Kornsbrust J, et al. Preclinical evaluation of lovastatin. Am J Cardiol 1988; 62: 16J–27J
Kornburst DJ, MacDonald JS, Chennekatu PP, et al. Toxicity of the HMG-Coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Toxicol 1989; 248: 498–505
Davenport RJ, Dennis MS, Warlow CP, et al. Gastrointestinal hemorrhage after acute stroke. Stroke 1996; 27: 421–4
Diez-Tejedor E, Alonso de Lecinana M, Counsell C, et al. Antithrombotic treatment in acute ischemia stroke. Neurologia 1995; 10: 48–54
Gámez R, Más R, Noa M, et al. Acute and subchronic oral toxicity of D-003 in rats. Toxicol Lett 2000; 118: 31–41
Gámez R, González JE, Rodeiro I, et al. In vivo genotoxic evaluation of D-003, a mixture of very long-chain aliphatic acids. J Med Food 2001; 4: 85–92
Gámez R, Rodeiro I, Fernández I, et al. A preliminary evaluation of the cytotoxic and genotoxic potential of D-003: a mixture of very long chain fatty acids. Teratog Carcinog Mutagen 2001; 21: 85–92
Rehg JE, Toth LA. Rodent quarantine programs: purpose, principles and practice. Lab Anim Sci 1998; 48: 438–47
Landsdown AB. Animal husbandry. In: Anderson D, editor. Experimental toxicology, the basic issues. Surrey, England: BIBRA, 1993, 101
Stevens K, Gallo M. Practical considerations in the conduct of chronic toxicity studies. In: Wallace II A, editor. Principles and methods of toxicology. New York: Raven Press Ltd, 1989: 237
Ford DJ. Nutrition and feeding. In: Poole T, editor. The care and management of laboratory animals. Bath, England: Longman Scientific and Technical, 1987: 35 and 189
Chhabra RS, Huff JE, Schwetz BS, et al. An overview of prechronic and chronic toxicity/carcinogenicity experimental study designs and criteria used by the National Toxicology Program. Environ Health Perspect 1990; 86: 313–21
Dorato MA, Voracnik M. The toxicologic assessment of pharmaceutical and biotechnologic products. In: Hayes W, editor. Principles and methods of toxicology. 3rd ed. New York: Raven Press, 1994: 189–219
Semler DE, Gad SC, Chengelis CP. The rat, chapter 2. In: Gad SC, Chengelis CP, editors. Animal models in toxicology.: Marcel Dekker Inc, USA 1992: 21–162
Morton B, Abbot D, Barclay R, et al. Removal of blood from laboratory mammals and birds. Lab Anim 1993; 27: 1–22
Voss G, Sachsse K. Red cell and plasma cholinesterase activities in microsamples of human and animal blood determined simultaneously by modified acetylthiocoline-DTNB procedure. Toxicol Appl Pharmacol 1970; 16: 764–72
Born G: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (L) 1962; 194: 927–30
Dejana E, Villa S, Gaetano G. Bleeding time in rats: a comparison of different experimental conditions. Thromb Haemost 1982; 48: 108–114
Long G, Symanowski T, Roback K. Precision in data acquisition and reporting of organ weights in rats and mice. Toxicol Pathol 1998; 26: 316–8
Evans LG, Butler WH. Histopathology in safety evaluation. In: Anderson D, editor. Experimental toxicology, the basic issues. Surrey, England: BIBRA, 1993: 119–129
Gad SC, Weil CS. Statistics for Toxicology. In: Hayes W, editor. Principles and methods of toxicology. 2nd ed. New York: Raven Press Ltd, 1989, 435–483
Bhatnagar D. Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol Ther 1998; 79: 205–30
Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24–33
Arruzazabala ML, Carbajal D, Mas R, et al. Effects of D-003, a new compound purified from sugar cane wax, on platelet aggregation in healthy volunteers: A randomized, double-blinded clinical study. Clinical Drug Invest 2002. In press
Wolford ST, Schoer RA, Gohs FX, et al. Reference range database for serum chemistry and haematology values in laboratory animals. J Toxicol Environ Health 1986; 18: 161–88
Matsuzawa T, Nomura M, Unno T. Clinical pathology references ranges of laboratory animals. J Vet Med Sci 1993; 55: 351–62
Alemán CL, Mas R, Rodeiro I, et al. Reference database of the main physiological parameters in Sprague Dawley rats from 6 to 32 months. Lab Anim 1998; 32: 457–66
Alemán CL, Mas R, Hernández C, et al. A 12 months study of policosanol oral toxicity in Sprague Dawley rats. Toxicol Lett 1994; 70: 77–87
Mesa AR, Más R, Noa M, et al. Toxicity of policosanol in Beagle dogs: one year study. Toxicol Lett 1994; 73: 81–90
Alemán CL, Mas R, Noa M, et al. Carcinogenicity of policosanol in Sprague Dawley rats: a 24 months study. Teratog Carcinog Mutagen 1994; 14: 239–49
Alemán CL, Noa M, Cerejido E, et al. Carcinogenicity of policosanol in mice: a 18 months study. Food Chem Toxicol 1995; 33: 573–8
Rodriguez M, García H. Teratogenic and reproductive studies of policosanol in the rats and rabbits. Teratog Carcinog Mutagen 1994; 14: 107–13
Rodríguez MD, García H. Evaluation of peri- and post-natal toxicity of policosanol in rats. Teratog Carcinog Mutagen 1998; 18: 1–7
Rodríguez MD, Sánchez M, García H. Multigeneration reproduction study of policosanol in rats. Toxicol Lett 1997; 90: 97–106
Mas R. Policosanol. Drugs Future 2000; 25: 569–86